Juno Bristol Myers Squibb News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Juno bristol myers squibb. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Juno Bristol Myers Squibb Today - Breaking & Trending Today

Considerations for CAR T-Cell Therapy Vs Bispecific Antibodies in Relapsed/Refractory Follicular Lymphoma

Patient preferences should be considered when selecting the optimal treatment regimen for patients with relapsed/refractory follicular lymphoma, as both CD19-directed CAR T-cell therapies and CD20-targeted bispecific antibodies can be efficacious in this population, according to a presentation by Caron A. Jacobson, MD, MMSc, at the 2023 SOHO Annual Meeting.
....

United States , Carona Jacobson , Juno Bristol Myers Squibb , Dana Farber Cancer Institute , Meeting Of The Society Hematologic Oncology , Effector Cell Therapy Program , European Hematology Association , International Conference On Malignant Lymphoma , Immune Effector Cell Therapy Program , Hematology Association , Bristol Myers Squibb , Malignant Lymphoma , Annual Meeting , Society Hematologic Oncology , Non Hodgkin Lymphoma , Follicular Lymphoma , Cart Cell , 2023 Soho Annual Meeting ,

Investegate |Oxford Biomedica PLC Announcements | Oxford Biomedica PLC: Full year results


 

I am truly proud of the Group s achievements over the period. We not only secured major new partnerships, brought the Oxbox manufacturing facility online in record time and responded to the challenges of the pandemic, but the team has also been able to rapidly work with AstraZeneca to provide a vaccine solution for COVID-19. This is a true testament to the world-class calibre and dedication of our staff in the year that the Group also gained entry to the FTSE250. Looking to the future, with the continued tide of growth in cell and gene therapy, coupled with the Group s leadership position in the lentiviral vector field, we are well positioned to advance both our own proprietary pipeline and that of our current and future partners programmes. ....

United Kingdom , Sam Rasty , Pierre Fabre , Mary Jane Elliott Matthew Neal , Stuart Paynter , Andrew Heath , Roch Doliveux , Oxford Astrazeneca , Oxford Biomedica Lentivector , John Dawson , Martin Diggle , Oxford Biomedica , Bristol Myers Squibb , Lorenzo Tallarigo , Juno Bristol Myers Squibb , Dame Kay Davies , Manufacturing Organisation , Contract Development , Oxford University Jenner Institute , Research Collaborations , Senior Executive Team , Boehringer Ingelheim , Stryker Corporation , Product Development , Juno Therapeutics Bristol Myers Squibb Partnership , Innovation Centre ,